2.1
Bevacizumab gamma (Lytenava, Outlook Therapeutics) is 'indicated in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)'.
2 Information about bevacizumab gamma
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for bevacizumab gamma.
Price
2.3
The list price of bevacizumab gamma is £470 for 1 vial of 7.5 mg per 0.3 ml solution (excluding VAT; company submission, accessed September 2024).
2.4
The company has a commercial arrangement. This makes bevacizumab gamma available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.